IL21 and B-cell chronic lymphocytic leukemia: Similarly, a recent study using NK cells from patients with B-cell chronic lymphocytic leukemia demonstrated enhanced cytotoxicity and ADCC when the cells were stimulated with IL-21 and rituximab, compared to control or rituximab treatment alone [27].